<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04368273</url>
  </required_header>
  <id_info>
    <org_study_id>M2019482</org_study_id>
    <nct_id>NCT04368273</nct_id>
  </id_info>
  <brief_title>Pd-1 Antibody Combined CCRT for Local Advanced Cervical Cancer.</brief_title>
  <acronym>CCRT+PD-1</acronym>
  <official_title>Phase I Study of Toripalimab Injection (Pd-1 Antibody) With Cisplatin Concurrent IMRT for Local Advanced Cervical Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of anti-PD-1 (toripalimab) combined with cisplatin&#xD;
      concurrent IMRT for locally advanced cervical cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The dose of toripalimab injection (pd-1 antibody) was 240mg/d, d1, i.v. every 14d, totally 4&#xD;
      cycles (56 days)&#xD;
&#xD;
      Concurrent chemoradiotherapy:&#xD;
&#xD;
      Cisplatin 40 mg/m2 i.v., d1, administered once a week; Radiotherapy: pelvic intensity&#xD;
      modulated radiotherapy, prescription dose DT: 50.4gy /2Gy/28f;After intraluminal irradiation&#xD;
      DT: 30-36 Gy/6Gy/5-6f 2f/w, complete the radiotherapy within 56 days.&#xD;
&#xD;
      Complete at least 4 cycles of concurrent chemoradiotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 8, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of acute adverse events</measure>
    <time_frame>up to 3 months complete treatment</time_frame>
    <description>safety evaluation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>3 months later after treatment</time_frame>
    <description>efficacy evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>up to 2 years</time_frame>
    <description>efficacy evaluation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PD-1 antibody combined CCRT for patients with local advanced cervical cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-1 antibody</intervention_name>
    <description>a new treatment drug combined radical radiotherapy concurrent chemotharpy</description>
    <arm_group_label>treatment</arm_group_label>
    <other_name>Toripalimab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. HPV positive in patients with cervical squamous cell carcinoma confirmed by&#xD;
             histopathology&#xD;
&#xD;
          2. Patients with local advanced (2018FIGO staged IB3, IIA -IVA) cervical cancer and had&#xD;
             not received any treatment before&#xD;
&#xD;
          3. There are measurable lesions according to the efficacy evaluation criteria for solid&#xD;
             tumors (RECIST) version 1.1&#xD;
&#xD;
          4. ECOG score 0-2&#xD;
&#xD;
          5. Expected survival ≥3 months&#xD;
&#xD;
          6. LVEF≥55%&#xD;
&#xD;
          7. Bone marrow function: neutrophils ≥1.5×109/L, platelets ≥100×109/L, hemoglobin ≥90g/L&#xD;
&#xD;
          8. Liver and kidney functions: serum creatinine ≤1.5 times the upper limit of normal&#xD;
             value;AST and ALT ≤2.5 times normal upper limit or ≤5 times normal upper limit in the&#xD;
             presence of liver metastasis;Total bilirubin ≤1.5 times the upper limit of normal&#xD;
             value, or ≤2.5 times the upper limit of normal value in patients with Gilbert's&#xD;
             syndrome&#xD;
&#xD;
          9. Thyroid function: normal range&#xD;
&#xD;
         10. Non-lactating patients&#xD;
&#xD;
         11. Sign the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with previous PD-1 or PD-L1 treatment&#xD;
&#xD;
          2. Patients with previous abdominal or pelvic radiotherapy&#xD;
&#xD;
          3. Other malignant tumors other than cervical cancer appeared in the past 5 years&#xD;
&#xD;
          4. Immunosuppressive drugs were used within 4 weeks prior to the first study treatment,&#xD;
             excluding nasal spray, inhaled or other local glucocorticoids or systemic&#xD;
             glucocorticoids in physiological doses (i.e., no more than 10 mg/ day prednisone or&#xD;
             equivalent doses of other glucocorticoids)&#xD;
&#xD;
          5. Active, known, or suspected autoimmune disease (congenital or acquired)&#xD;
&#xD;
             ), such as interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary&#xD;
             inflammation, vasculitis, nephritis, thyroiditis, etc. (vitiligo or childhood asthma&#xD;
             has been completely relieved, adults without any intervention can be included;Patients&#xD;
             with type 1 diabetes with good insulin control can also be enrolled, as can&#xD;
             hypothyroidism caused by autoimmune thyroiditis that requires hormone replacement&#xD;
             therapy.)&#xD;
&#xD;
          6. Known allogeneic organ transplantation (except corneal transplantation) or allogeneic&#xD;
             hematopoietic stem cell transplantation&#xD;
&#xD;
          7. Known allergy to any component of the drug&#xD;
&#xD;
          8. Serious medical diseases that are not under control, such as the combination of&#xD;
             serious medical diseases, including severe heart disease, cerebrovascular disease,&#xD;
             uncontrolled diabetes, uncontrolled hypertension,uncontrolled infection, active peptic&#xD;
             ulcer&#xD;
&#xD;
          9. Received other experimental drugs or participated in other drugs within 30 days of&#xD;
             initial administration clinical research on the purpose of anticancer therapy&#xD;
&#xD;
         10. Severe infection occurred within 4 weeks prior to study treatment, including, but not&#xD;
             limited to, hospitalization hospital treatment of infection complications, bacteremia&#xD;
             or severe pneumonia&#xD;
&#xD;
         11. Human immunodeficiency virus (HIV) positive&#xD;
&#xD;
         12. Hepatitis B surface antigen (HBsAg) positive, and the peripheral blood hepatitis B&#xD;
             virus deoxygenation the titer of ribonucleic acid (HBV-DNA) was detected in subjects&#xD;
             ≥1×10&lt;3&gt; IU/mL&#xD;
&#xD;
         13. Hepatitis C virus (HCV) antibody positive or human immunodeficiency virus (HIV)&#xD;
             Antibody positive and HCV RNA positive&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junjie Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University 3rd Hospital radiation oncology department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ping Jiang, MD</last_name>
    <phone>010-82266699</phone>
    <phone_ext>4912</phone_ext>
    <email>drjiangping@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University 3rd Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijng</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 25, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2020</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University Third Hospital</investigator_affiliation>
    <investigator_full_name>Junjie Wang</investigator_full_name>
    <investigator_title>Department director</investigator_title>
  </responsible_party>
  <keyword>PD-1</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>concurrent chemoradiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

